GlobeNewswire by notified

Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022

Share

Pixium Vision announces reaching itsenrollment target in the European pivotal trial PRIMAvera and implantations plannedto be completed by end 2022

  • The target number of 38 patients have been enrolled at clinical sites in France, Germany, the UK, the Netherlands, and Italy
  • Waiting list for additional patients initiated to replace potential pre-implantation drop-outs and ineligibility
  • Implantations due to be completed by the end of 2022; PRIMAvera read-out expected around the end of 2023

Paris, France, September19, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD), also known as Geographic Atrophy.

A total of 38 patients have been enrolled in the PRIMAvera study (NCT04676854), an open-label, baseline-controlled, non-randomized, multi-center, prospective single-arm pivotal trial. A waiting list for additional patients has also been established to replace any of the current 38 patients who could prove ineligible for implantation or drop out before implantation takes place. The PRIMAvera study aims to confirm the safety and clinical benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe.

The study was initiated in Q4 2020 in France, where the first patient was enrolled in December 2020. Pixium Vision has since established additional clinical sites and implanted patients in France, Germany, the UK, the Netherlands, and Italy. Implantations are due to be completed by the end of 2022, and a read-out of the PRIMAvera study's primary endpoints is expected around the end of 2023.

"We are very pleased to have reached the target patient number in our pivotal PRIMAvera study, which has been making great progress since it was initiated in late 2020," said Professor Frank Holz, the lead investigator for Germany and scientific coordinator of the PRIMAvera study."We are excited to be advancing this innovative technology towards the marketwhere patients suffering from dry AMD could benefit. We are looking forward to completing the implantations by the end of the year and announcing the study's read-out around the end of 2023."

The PRIMAvera study design is based on the positive data generated in a French feasibility study, showing the ability of patients with dry AMD to improve visual acuity with the Prima System. The primary efficacy endpoint of the PRIMAvera study is the proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline after 12 months, and the primary safety endpoint is the number and severity of device and procedure-related serious adverse events at 12 months follow-up. The study will include three years of follow-up, with an assessment of the primary endpoints at 12 months after implantation.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.

For more information: To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.http://www.pixium-vision.com/fr

Follow us on To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.@PixiumVision; To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.facebook.com/pixiumvision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.linkedin.com/company/pixium-vision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Contacts

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68
Media Relations
LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor Relations
LifeSci Advisors
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 76 735 01 31

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sword Group: NOTICE OF CONVOCATION TO THE SHAREHOLDERS FOR THE ANNUAL ORDINARY GENERAL MEETING OF THE COMPANY28.3.2024 18:00:00 CET | Press release

General Meeting on April 29, 2024, at 11:00 am at the registered office to deliberate on the following agenda: Under the authority of the General Meeting acting under the quorum and majority conditions of an Ordinary General Meeting: - Reading of the management report of the Board of Directors including the group management report and feedback on the conclusion of agreements referred to in article L.441-7 of the amended law of August 10, 1915, for the financial year ended December 31, 2023; - Reading of the report of the approved statutory auditor on the 2023 annual accounts, the group's consolidated financial statements, and on the execution of its mission; - Approval of the statutory accounts as of December 31, 2023; - Approval of the consolidated accounts as of December 31, 2023; - Allocation of the statutory exercise results as of December 31, 2023; - Discharge to the directors for their management for the financial year 2023; - Renewal of Mr. Jacques Mottard's director term; - Ren

Sword Group: H2 2023 Report of the Liquidity Agreement28.3.2024 18:00:00 CET | Press release

Sword Group - H2 Report of the Liquidity Agreement contracted with ODDO BHF from 01/07/2023 au 31/12/2023 Under the liquidity contract awarded by Sword Group to ODDO BHF, as of 31/12/2023, the following resources appeared on the account of liquidity: 8,959 shares €359,040 - Number of transactions executed during the semester at purchase: 1,116 - Number of transactions executed during the semester on sale: 1,080 - Volume exchanged over the semester upon purchase: 34,943 shares for an amount of €1,319,183 - Volume exchanged over the semester for sale: 38,733 shares for an amount of €1,455,889 As a reminder, during the last balance sheet of 30/06/2023, the following resources appeared in the liquidity account: 12,749 shares €353,334 The implementation of the liquidity contract is carried out in accordance with AMF Decision No. 2018-01 dated July 2, 2018, establishing liquidity contracts on equity securities as accepted market practice. About Sword Group Sword has 3,000+ IT/Digital & Softw

Sword Group: Availability of the 2023 Financial Report28.3.2024 18:00:00 CET | Press release

Sword Group - Availability of the 2023 Financial Report According to the current regulations, Sword Group announces that its 2023 Financial Report has been made available to the public. It was sent to the Commission de Surveillance du Secteur Financier (CSSF) and was also filed with the Luxembourg Stock Exchange. It can be viewed and downloaded on the website of the company:Regulated Information Dividend €1.7 gross per shre Pending approval at the Annual General Meeting on April 29. Ex-date: April 30, 2024 - Payment: May 3, 2024 Calendar 25/04/24 | 2024 First Quarter Revenue 18/07/24 | 2024 Second Quarter Revenue About Sword Group Sword has 3,000+ IT/Digital specialists present over 5 continents to accompany you in the growth of your organisation in the digital age. As a leader in technological and digital transformation, Sword has a solid reputation in software publishing and in complex IT & business project management. Sword optimises your processes and enhances your data. Contact At

Sword Group: Information on the Number of Shares and Voting Rights at 29/02/202428.3.2024 18:00:00 CET | Press release

INFORMATION ON THE NUMBER OF SHARES AND VOTING RIGHTS AT 29/02/2024 Total Number of Shares: 9,544,965 Number of theoretical voting rights: 9,544,965 Number of exercisable voting rights: 9,398,264 Dividend €1.7 gross per shre Pending approval at the Annual General Meeting on April 29. Ex-date: April 30, 2024 - Payment: May 3, 2024 Calendar 25/04/24 | 2024 First Quarter Revenue 18/07/24 | 2024 Second Quarter Revenue About Sword Group Sword has 3,000+ IT/Digital specialists present over 5 continents to accompany you in the growth of your organisation in the digital age. As a leader in technological and digital transformation, Sword has a solid reputation in software publishing and in complex IT & business project management. Sword optimises your processes and enhances your data. Contact Attachment Sword Group SE Number of Shares & voting Rights published on 28032024

Sword Group: Availability of preparatory documents for the Ordinary General Meeting of 29 April 202428.3.2024 18:00:00 CET | Press release

The Ordinary General Meeting of Shareholders of Sword Group SE will be held at 11 a.m. on 29 April 2024. The notice of meeting including the agenda was published in the RESA (Recueil électronique des sociétés et associations) and in the Luxemburger Wort on 28 March 2024. The terms and conditions for attending and voting at this meeting are set out in this notice. The documents and information that must be provided at the General Meeting, together with the single form for participation, postal voting and proxy (the "Single Form"), are available on the Company's website here and at the registered office for an uninterrupted period commencing on the day of publication of this notice and ending on the day after the General Meeting. Upon presentation of their shares, shareholders may obtain copies of the documents free of charge under the applicable legal conditions. Registered shareholders must send the Company the duly completed, dated and signed Single Form, together, where applicable, w

HiddenA line styled icon from Orion Icon Library.Eye